title: Utilizing RNA interference to enhance cancer drug discovery.
abstract: With the development of RNA interference (RNAi) libraries, systematic and cost-effective genome-wide loss-of-function screens can now be carried out with the aim of assessing the role of specific genes in neoplastic phenotypes, and the rapid identification of novel drug targets. Here, we discuss the existing applications of RNAi in cancer drug discovery and highlight areas in this process that may benefit from this technology in the future.
authors.affiliation: The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Iorns
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Lord
authors.forename: Nicholas
authors.initials: N
authors.lastname: Turner
authors.forename: Alan
authors.initials: A
authors.lastname: Ashworth
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016158:Genes, p53; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D009857:Oncogenes; D034622:RNA Interference; D034741:RNA, Small Interfering; D013678:Technology, Pharmaceutical
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering